Expert Opinion on Investigational Drugs

Papers
(The TQCC of Expert Opinion on Investigational Drugs is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL113
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy86
Theranostic strategies in sarcoma: preliminary clinical evidence55
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men54
Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials46
Current status and perspective of immunotherapy for head and neck squamous cell carcinoma44
Endoglin-targeted cancer therapies: current status and opportunities41
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD38
SGLT2 inhibitors: an evidence-based update on cardiovascular implications35
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology35
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?30
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome29
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies29
Management of inflammaging in kidney diseases: focusing on the current investigational drugs29
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development28
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval27
The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis26
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis25
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets25
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy25
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials25
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development24
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su24
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors24
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies23
Mass balance and absolute bioavailability of avenciguat ( 14 C) after intravenous or oral administration in healthy male participants23
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?22
Endothelin receptor antagonists for diabetic kidney disease: back to the future?22
Odronextamab: a bispecific antibody for follicular lymphoma21
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease20
Investigational drugs for the treatment of dysmenorrhea20
Potassium channel modulators and schizophrenia: an overview of investigational drugs20
IgA nephropathy: an overview of drug treatments in clinical trials19
Duchenne muscular dystrophy: promising early-stage clinical trials to watch19
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development19
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia18
Recent developments in adjunct therapies for type 1 diabetes18
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials17
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal17
Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?17
What is the progress of experimental drug development for fibromyalgia?17
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study17
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options16
Investigational new drugs for the treatment of leishmaniasis16
Current experimental and early investigational agents for cardiac fibrosis: where are we at?16
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration16
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials16
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists15
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer15
SOT201: cis -acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors15
Frontotemporal dementia: from genetics to therapeutic approaches15
Preclinical therapeutics for sickle cell disease: modern developments and future considerations14
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)14
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations14
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents14
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions14
NF1 alterations in cancers: therapeutic implications in precision medicine14
Advancements in longevity pharmacology research – are we finally seeing clinical progression?14
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects14
Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis13
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions13
Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?13
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease13
Progress in the treatment of anal cancer: an overview of the latest investigational drugs13
Investigational drugs for the treatment of olfactory dysfunction13
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress13
Assessing the clinical progress of the bispecific nanobody sonelokimab13
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa13
Navafenterol for chronic obstructive pulmonary disease therapy13
Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?13
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents12
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials12
Immunotherapeutic strategies for treating opioid use disorder and overdose12
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?12
Clinical development of tri-specific antibodies for immune-oncology12
JAK inhibitors for rheumatoid arthritis12
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia11
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus11
An update on novel investigational agents for the treatment of primary biliary cholangitis11
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis11
Investigational thrombolytic drugs for acute ischemic stroke11
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer11
Investigational agents for ischaemic cardiomyopathy treatment: preclinical and early phase insights11
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study11
Investigational new drugs for the treatment of Dravet syndrome: an update11
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep10
Investigational anti IL-13 asthma treatments: a 2023 update10
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies10
Prospects of current AXL-targeting therapies in early phase cancer trials10
Tafoxiparin effects on cervical ripening and labor augmentation10
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress10
Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition10
Pharmacological agents for bone fracture healing: talking points from recent clinical trials10
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma10
IRAK signaling in cancers: mechanisms, targeting, and clinical implications10
Inflammation and Huntington’s disease – a neglected therapeutic target?10
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials9
Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis9
Mantle cell lymphoma: what clinical progress in the last 5 years?9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension9
Assessing potential of psilocybin for depressive disorders9
Menin inhibitors for adult acute myeloid leukemia: 2025 update9
The impact of current investigational drugs for acne on future treatment strategies9
The latest investigational drugs for patients with allergic rhinitis9
0.20087718963623